PanMediso Holdings

PanMediso Holdings Committed to providing solutions for nuclear medicine diagnosis and treatment technologies we provide GMP-level production and global supply of new isotopes.

PanMediso Holdings is a company dedicated to the research, development, production, and sales of medical isotopes. Headquartered in Shenzhen, China, our core technical team comprises top talents in the field of isotopes from both China and the United Kingdom. With profound expertise in isotope research and production, we are committed to establishing an internationally integrated nuclear medicine company across the entire industry chain.

PanMediso Spotlight｜Over $700 Million! Novartis Expands Investment in RadiopharmaceuticalsOn November 18, 2024, Ratio Th...
21/11/2024

PanMediso Spotlight｜Over $700 Million! Novartis Expands Investment in Radiopharmaceuticals

On November 18, 2024, Ratio Therapeutics signed a global exclusive licensing and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis, to develop next-generation SSTR2-targeted radiopharmaceuticals.

Under the terms of the agreement, Ratio will receive up to $745 million in upfront and potential milestone payments, along with tiered royalty rights.

This collaboration will focus on advancing preclinical activities to identify SSTR2-targeted drug candidates, while Novartis will oversee the remaining development, manufacturing, and commercialization efforts.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Covalent Targeted Radiopharmaceuticals Enhance Radionuclide Therapy EfficacyA 2024 Nature article ti...
21/11/2024

PanMediso Spotlight｜Covalent Targeted Radiopharmaceuticals Enhance Radionuclide Therapy Efficacy

A 2024 Nature article titled "Covalent Targeted Radioligands Potentiate Radionuclide Therapy" introduced a novel class of covalent targeted radiopharmaceuticals (Covalent Targeted Radioligand, CTR). By leveraging ligand-directed bonding reactions and "click chemistry," this innovative approach achieves covalent binding between radioligands and tumor targets, addressing the long-standing challenge of balancing rapid blood clearance and prolonged tumor retention in traditional radiopharmaceuticals.

Focusing on fibroblast activation protein (FAP) as a target, the CTR drugs demonstrated enhanced tumor uptake, extended tumor retention, and improved therapeutic efficacy in both mouse models and cancer patients. This groundbreaking technology holds significant clinical potential and is adaptable to the development of other radiopharmaceuticals targeting diverse biological markers.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Novartis' New Radioligand Cancer Therapy Drug Submitted for Approval in China!On November 13, 2024, ...
15/11/2024

PanMediso Spotlight｜Novartis' New Radioligand Cancer Therapy Drug Submitted for Approval in China!

On November 13, 2024, Novartis' radioligand cancer therapy drug, Lutetium [177Lu] Trastuzumab Injection (Pluvicto), was accepted by China’s National Medical Products Administration (CDE) for review. This PSMA-targeted radioligand therapy was FDA-approved in March 2022 for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This submission indicates that Pluvicto could soon be available in China, offering a new, precision treatment option for prostate cancer patients.

Additionally, Novartis’ other radiopharmaceutical, the 68Ga-Gozetotide injection kit, was also accepted, intended for PET scans to identify PSMA-positive prostate cancer lesions. Radiopharmaceuticals' unique "theranostic" capability combines precise tumor targeting with effective cancer cell eradication, showcasing significant therapeutic advantages.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Theranostics（IF=12.4）：Alpha-Nuclide Radiation-Driven Bystander Effect | Professor Fei Yu's TeamRecen...
15/11/2024

PanMediso Spotlight｜Theranostics（IF=12.4）：Alpha-Nuclide Radiation-Driven Bystander Effect | Professor Fei Yu's Team

Recently, Professor Fei Yu's team published China's first preclinical study on alpha-nuclides 212Pb/212Bi, titled “Role of Damaged Mitochondrial Transfer in Alpha-Particle Generator 212Pb Radiation-Induced Bystander Effect” in Theranostics (IF=12.4). This study explores how radiation-induced damaged mitochondria act as signaling mediators, facilitating the bystander effect in cancer treatment.

The research indicates that molecules in the ICCM may influence the fate of bystander cells, suggesting that indirect tumor cell damage can achieve a broader therapeutic impact. This effect enhances the efficacy of alpha-nuclide therapy in targeting tumor cells beyond the irradiated area, offering a promising approach for cancer treatment.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜First Human Study of the GPC3-Targeting Peptide Radiopharmaceutical 68Ga-RAYZ-8009This study introdu...
08/11/2024

PanMediso Spotlight｜First Human Study of the GPC3-Targeting Peptide Radiopharmaceutical 68Ga-RAYZ-8009

This study introduces the first human application of the GPC3-targeting radiopharmaceutical 68Ga-RAYZ-8009, focusing on evaluating its potential for diagnosing hepatocellular carcinoma (HCC). By combining with PET/CT, 68Ga-RAYZ-8009 effectively visualizes HCC lesions and provides supplementary information to the existing CT and MRI LI-RADS systems.

The study's results indicate that the drug has no significant side effects and can clearly display the hypervascularity of liver tumors in a short time through dynamic scanning, while presenting a good distribution in static images. Preliminary clinical data suggest that 68Ga-RAYZ-8009 not only aids in the early diagnosis of HCC but also has potential as a therapeutic radiopharmaceutical.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Novartis Nuclear Medicine Revenue Exceeds $1 Billion in the First Three QuartersNovartis' third-quar...
08/11/2024

PanMediso Spotlight｜Novartis Nuclear Medicine Revenue Exceeds $1 Billion in the First Three Quarters

Novartis' third-quarter report reveals that global sales of the radioligand therapy Pluvicto reached $386 million, a 50% year-over-year increase, with year-to-date sales surpassing $1.04 billion, up 47%.

Pluvicto is a radioligand therapy that combines a small molecule targeting PSMA (prostate-specific membrane antigen) with the radioactive isotope 177Lu.

According to Novartis' financial report, the company has submitted a filing for Pluvicto's use in second-line treatment of PSMA-positive mCRPC. Once approved, this indication is expected to drive Pluvicto's sales to new heights for the year.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Potential Applications of Supramolecular Chemistry in Cancer Diagnostics and RadiopharmaceuticalsSup...
01/11/2024

PanMediso Spotlight｜Potential Applications of Supramolecular Chemistry in Cancer Diagnostics and Radiopharmaceuticals

Supramolecular chemistry shows great potential in cancer treatment and diagnosis, with its material systems capable of rapid generation through self-assembly, flexible chemical synthesis, and reversible non-covalent interactions.

On October 28, 2024, Guillermo Moreno-Alcántar, Angela Casini, and others from the Technical University of Munich (Technische Universität München) published a review in Nature Reviews Chemistry. This review focuses on the application advancements of self-assembled complexes and mechanically interlocked molecules, such as metal-organic cages and rotaxanes, as well as in situ-formed supramolecular aggregates in radiopharmaceuticals, emphasizing their potential as the next generation of radiopharmaceutical agents.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜China Issues "Three-Year Action Plan for High-Quality Development of the Nuclear Technology Applicat...
01/11/2024

PanMediso Spotlight｜China Issues "Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026) "
As per the Plan, by 2026, the annual direct economic output of the nuclear technology application industry will be to 400 billion RMB, with key technological breakthroughs to be achieved in fields such as medicine, agriculture, and security, and strengthen innovation capabilities and industry standards.

https://www.caea.gov.cn/n6760339/n6760347/c10625020/content.html

The Plan outlines seven primary tasks:
Infrastructure Upgrades: Promote the construction of medical isotope production reactors and optimize existing facilities to fulfill both research and production functions.
Key Technology Advancement: Strengthen foundational research, develop new drugs, radiotherapy technologies, and high-end equipment, and explore the potential applications of nuclear technology in emerging industries like quantum computing, energy storage, and brain-computer interfaces.
Isotope Supply : Accelerate the large-scale production of medical isotopes like Molybdenum-99 and Iodine-125, advance industrial isotope research for isotopes such as Scandium-47 and Iridium-192, and ensure an independent supply of critical isotope products.
Industry Application Promotion: Expand nuclear technology applications in industries such as manufacturing, agriculture, medicine, environmental protection, and public safety to support industrial transformation and upgrading.
New Application Scenarios: Drive the integration of nuclear technology with biotechnology, new materials, and advanced manufacturing, and develop a cross-disciplinary "Nuclear Technology +" platform.
Industrial Cluster Development: Foster collaboration along the industry chain, support the growth of industrial clusters and leading enterprises.
Standards System Establishment: Establish and improve the standard system for nuclear technology applications, promoting mutual recognition of standards domestically and internationally.

The Plan outlines various supportive measures to boost industry growth:
Financial and Tax Support: Provide support to nuclear technology application enterprises through national guiding funds and innovative financial instruments.
Industry Regulation Optimization: Streamline approval processes for radioactive drugs and nuclear medical equipment, and strengthen radiation safety and environmental protection regulations.
Basic Services and Talent Development: Promote the construction of public service platforms for testing, inspection, and validation, and support collaborative talent cultivation between universities and enterprises.
Industry Promotion: Enhance public science education and international promotion to aid the global expansion of China's nuclear technology application industry.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Application of Nanomedicine Drug Delivery Systems (DDS)Nanovectors have become an essential tool in ...
25/10/2024

PanMediso Spotlight｜Application of Nanomedicine Drug Delivery Systems (DDS)

Nanovectors have become an essential tool in Targeted Alpha Therapy (TAT) due to their ability to efficiently deliver α-particles directly to tumor cells while precisely releasing radioactive particles. Nanotechnology provides a solid scientific foundation for the clinical translation of TAT, particularly in cases requiring higher doses of radioactivity. Nanocarriers are considered one of the most promising solutions to reduce toxic side effects in such clinical settings.

Common nanocarriers for α-radioisotope drugs fall into three categories: lipid-based nanoparticles (NPs), polymer nanoparticles, and inorganic nanoparticles.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Sanofi Invests Another €300 Million to Develop Next-Gen RadiopharmaceuticalsOn October 17, Sanofi an...
25/10/2024

PanMediso Spotlight｜Sanofi Invests Another €300 Million to Develop Next-Gen Radiopharmaceuticals

On October 17, Sanofi announced a new collaboration agreement with Orano Med to accelerate the development of next-generation radioligand therapies. Under the agreement, Sanofi will make a €300 million equity investment in Orano Med, acquiring approximately 16% of the new entity, valued at €1.9 billion (about $2.055 billion).

The agreement specifies that, leveraging Orano Med’s expertise and its radioligand drug pipeline, Sanofi and Orano Med will jointly focus on the discovery, design, and clinical development of alpha-particle radioligand therapies based on the lead-212 isotope.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Radiation Risk in Medical ExaminationsUltrasound (B-Scan)No radiation risk. Ultrasound uses sound wa...
18/10/2024

PanMediso Spotlight｜Radiation Risk in Medical Examinations

Ultrasound (B-Scan)
No radiation risk. Ultrasound uses sound waves to pe*****te the body and form images based on the reflected waves. It is not associated with radiation, so there is no need to worry about radiation during an ultrasound examination.

Magnetic Resonance Imaging (MRI)
No radiation risk. Although MRI involves the use of atomic nuclei, it does not involve radioactivity. MRI uses magnetic fields and radiofrequency waves, which do not produce radiation.

X-ray (DR)
X-rays are commonly used to check the lungs, bones, etc. The radiation dose typically ranges from 0.02 to 0.1 millisieverts (mSv), which is equivalent to the radiation received during a long-haul flight.

CT Scan
A CT scan uses X-rays to create detailed images of the body. Although the radiation dose from a CT scan is higher than that of a standard X-ray, it is still relatively low and usually does not pose a significant health risk.

Nuclear Medicine
Nuclear medicine involves the injection of a radioactive tracer to produce images. The radiation comes from the tracer rather than the equipment. The radiation dose varies depending on the tracer used but generally falls within a low range.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

PanMediso Spotlight｜Peking University and Changping Laboratory Make Major Advances in RadiopharmaceuticalsThe team led b...
18/10/2024

PanMediso Spotlight｜Peking University and Changping Laboratory Make Major Advances in Radiopharmaceuticals

The team led by Liu Zhibo at Peking University and Changping Laboratory has developed an innovative Covalent Targeted Radioligand (CTR), a new type of radiopharmaceutical. This innovation overcomes the traditional challenge of balancing "rapid clearance" and "long retention" in radiopharmaceuticals.

CTR has demonstrated its effectiveness at the molecular, cellular, mouse, and patient levels, and has shown higher tumor imaging sensitivity in clinical studies compared to traditional methods, making it a promising candidate for the next generation of more effective radiopharmaceuticals.

We PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health.

Address

56F, Changfujinmao Building, Shihua Road, Futian Free Trade Zone
Shenzhen
518038

Telephone

+8675582567092

Website

Alerts

Be the first to know and let us send you an email when PanMediso Holdings posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to PanMediso Holdings:

Shortcuts

Share

Category